Commercial And Pipeline Insight: Allergic Rhinitis : Market Research Report

Commercial And Pipeline Insight: Allergic Rhinitis

Published by: Datamonitor

Published: Oct. 8, 2007 - 319 Pages

ABOUT DATAMONITOR HEALTHCARE: About the Respiratory and Infectious Disease pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Objective of the analysis; Datamonitor insight into the allergic rhinitis market; Contributing experts; Related reports; Upcoming related reports
CHAPTER 2 MARKET DEFINITION AND OVERVIEW: Market definition for this report; Allergic rhinitis disease background; Asthma is main and most important co-morbidity; Segmentation; Allergic rhinitis prevalence; Allergic rhinitis prevalence in children; Current market situation; Unmet needs in allergic rhinitis; Clinical unmet needs; Lack of a cure; Uncontrolled disease; Drugs do not impact co-morbidities sufficiently; Environmental unmet needs; Compliance is relatively low; Pipeline overview; Key companies involved in the allergic rhinitis market; Schering-Plough; Pfizer; Sanofi-Aventis; GlaxoSmithKline; Merck & Co; UCB; Sepracor; Companies involved in immunotherapy; Clinical trial design in allergic rhinitis; Endpoints; Symptom scores are most often used in clinical trials; Specific safety measures remain essential; Objective inflammatory endpoints are key for new anti-inflammatory therapies; Study population; Pediatric trials need some adaptation; Comparator drug
CHAPTER 3 COUNTRY MARKET ASSESSMENTS: Summary of environmental issues affecting the allergic rhinitis market; Seven major market opportunities and threats; Opportunities; Over-the-counter (OTC) status may extend revenue after patent expiry; Increasing prevalence of allergic rhinitis; Allergy seasons start earlier, last longer and are more intense; EMEA harmonizes drug approval process; Smaller companies helped by European regulators; Threats; Governments try to stop increasing healthcare expenditure by controlling pricing and reimbursement; Parallel trading threatens return on investment; US: opportunities and threats; Allergic rhinitis market overview; Opportunities; The OTC market is becoming more important in the US; FDA initiatives to decrease product development times; US is the only country to allow direct-to-consumer (DTC) advertising of prescription medicines; Threats; Reimbursement controls decrease healthcare expenditure in the US; Implementation of Medicare Part D influences US healthcare market; Parallel trading could increase due to Medicare D's 'donut hole'; Prescription Drug User Fee Act (PDUFA) likely to increase fees; Japan: opportunities and threats; Allergic rhinitis market overview; Opportunities; Separation of manufacturing and marketing entities benefits both Japanese and foreign companies; Japan shows initiatives to open its market; Threats; Price cuts still dominate pricing and reimbursement in Japan; Increasing uptake of generics; Lengthy approval process slows down access to the Japanese market; France: opportunities and threats; Allergic rhinitis market overview; Opportunities; Generics use is still relatively low in France; Pricing and reimbursement negotiations to be shortened by new agency; Threats; France increases its pricing and reimbursement efforts; Germany: opportunities and threats; Allergic rhinitis market overview; Opportunities; Encouraging environment for novel drug development; ePharmacy and mail-order drugs legalized; Threats; Reimbursement controls are important in decreasing healthcare expenditure in Germany; Generic penetration in Germany is relatively high; Italy: opportunities and threats; Allergic rhinitis market overview; Opportunities; Generic drugs play a small role in Italy; Reimbursement negotiations are less restrictive; Threats; Italy increases its pricing and reimbursement efforts; Spain: opportunities and threats; Allergic rhinitis market overview; Opportunities; The pharmaceutical industry implements strategies to reduce parallel exportation; Health ministry introduces 'Spanish national formulary'; Threats; The introduction of a new medicines bill increases the focus on cost containment in Spain; The profile of generics is being raised in Spain; UK: opportunities and threats; Allergic rhinitis market overview; Opportunities; The UK offers an attractive market; The pricing and reimbursement environment in the UK is relatively non-restrictive; Threats; Lack of allergy knowledge in primary care setting; Lack of allergy specialists; The UK enjoys a strong generics market; The post-guidance and pre-guidance effects of NICE are a significant concern
CHAPTER 4 DRUG ANALYSIS & FORECASTS: Overview for oral antihistamines; Patient potential; Comparative forecasts; Pipeline summary; Zyrtec; Zyrtec forecast assumptions; Trial data; Xyzal; Xyzal forecast assumptions; Trial data; Telfast/Allegra; Telfast/Allegra forecast assumptions; Trial data; Claritin; Claritin forecast assumptions; Trial data; Aerius/Clarinex; Aerius/Clarinex forecast assumptions; Trial data; Pipeline drugs in the antihistamines class; Bilastine; CP-118; Late-stage development compounds recently discontinued; Overview for nasal corticosteroids; Patient potential; Comparative forecasts; Pipeline summary; Nasonex; Nasonex forecast assumptions; Trial data; Flixonase/Flonase; Flixonase/Flonase forecast assumptions; Trial data; Nasacort; Nasacort forecast assumptions; Trial data; Rhinocort; Rhinocort forecast assumptions; Trial data; Pipeline drugs in the nasal corticosteroid class; Veramyst; Omnair; Nasal steroid/antihistamine combination; Innovative anti-inflammatory projects; Late-stage development compounds recently discontinued; Overview for oral antihistamine/decongestant combinations; Patient potential; Comparative forecasts; Zyrtec-D; Zyrtec-D forecast assumptions; Trial data; Allegra-D; Allegra-D forecast assumptions; Trial data; Clarinex-D; Clarinex-D forecast assumptions; Trial data; Overview for nasal antihistamines; Patient potential; Pipeline summary; Astelin; Astelin forecast assumptions; Trial data; Pipeline drugs in the nasal antihistamine class; Patanase; Other pipeline drugs in the nasal antihistamine class; Overview for antileukotrienes; Patient potential; Pipeline summary; Singulair; Singulair forecast assumptions; Trial data; Onon; Onon forecast assumptions; Trial data; Pipeline drugs in the antileukotrienes class; Loratadine/montelukast combination; Overview for nasal decongestants; Overview for immunotherapy; Current market overview; Patient potential; Moving towards baseline therapy; Immunotherapy is shown to be effective and safe; Studies show long-term relief after discontinuation of immunotherapy; Immunotherapy is thought to prevent new sensitizations; Studies suggest role for immunotherapy in the prevention of asthma; More studies needed to evaluate the safety of immunotherapy in asthma; Showing safety of immunotherapy in children is an important step for expanding the market; Immunotherapy can be cost-effective; Significant commercial opportunity; Pipeline summary; Companies involved in immunotherapy; ALK-Abelló; Stallergènes; Allergy Therapeutics; Dynavax; Fornix Biosciences; Curalogic; Greer Laboratories; Allergopharma; HAL Allergy; Non allergen-based immunotherapy; Cytos Biotechnology; CMP Therapeutics; Cobalis; Data definitions, limitations and assumptions; Over-the-counter (OTC) sales; Standard units; Japanese market data; Derivation of sales forecasts and pricing trends; Regional launch dates for new products; Generic erosion and pricing assumptions; Forecasts; Forecast methodology; Strategic scoping and focus
BIBLIOGRAPHY: Papers; Websites; Datamonitor reports
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS: Summary allergic rhinitis market data; Antihistamines market data; Nasal corticosteroids market data; Antihistamine/decongestant combination market data; Antileukotrienes market data; Nasal anti-allergic agents market data
APPENDIX B - MARKET FORECAST DATA: Seven major markets; M5EU; US; Japan; France; Germany; Italy; Spain

Abstract

Introduction

The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.

Scope

Indication-based forecasts for allergic rhinitis products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Assessment of the remaining unmet clinical needs in allergic rhinitis, analyzing the potential of new targeted therapies

Highlights

The allergic rhinitis market was worth about $10 billion in 2006 and has been decreasing in value over the last few years due to patent expiries and limited levels of innovation. The top 2 drug classes prescribed for the treatment of allergic rhinitisoral antihistamines and nasal corticosteroidsaccounted for 77% of the total sales in this market. At least 3 major allergic rhinitis players have developed and launched an oral antihistamine/decongestant fixed dose combination. However, several practical concerns have limited the use of these treatments and none of the products have reached sales as high as their single antihistamine component. The immunotherapy market is moving from a niche position towards baseline therapy. Datamonitor expects a sublingual tablet for the treatment of grass allergy (such as Grazax) to be able to reach annual sales of $780m to $1.3 billion, depending on the patient population targeted, the length of administration and price of the product.

Reasons to Purchase

Identify key opportunities and threats that will impact the use and uptake of new and existing products Quantify the future size and scope of the allergic rhinitis market and predict the future performance of key compounds Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

Please Note: This product is delivered as an Zip file.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial And Pipeline Insight: Allergic Rhinitis

Table of Contents

Abstract